|
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent novel and promising findings include additional abnormalities in key pathways associated with thyroid tumorigenesis (RET-Ras-BRAF-MEK; RET-beta-cateinin; TRK-PI3K-AKT; and MDM-p53-PTEN), single-nucleotide polymorphisms associated with thyroid cancer susceptibility, epigenetic silencing, alternative splicing, and gene expression abnormalities.
|
19907326 |
2010 |
|
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Initiation and progression of thyroid cancer involves multiple genetic and epigenetic alterations, of which mutations leading to the activation of the MAPK and PI3K-AKT signaling pathways are crucial.
|
21878896 |
2011 |
|
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.
|
31289610 |
2019 |
|
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
|
26456083 |
2016 |
|
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MicroRNA-126 suppresses proliferation of undifferentiated (BRAF(V600E) and BRAF(WT)) thyroid carcinoma through targeting PIK3R2 gene and repressing PI3K-AKT proliferation-survival signalling pathway.
|
26384552 |
2015 |
|
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In particular, SGK1 was found to be essential for proliferation and survival of thyroid cancer cells harboring PI3K-activating mutations.
|
29055016 |
2017 |
|
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thyroid cancer (TC) is frequently associated with BRAF or RAS oncogenic mutations and RET/PTC rearrangements, with aberrant RAF-MEK-ERK and/or PI3K pathway activation.
|
26265449 |
2015 |
|
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The initiation of thyroid cancer is often triggered by a genetic mutation in the phosphortidylinositol-3 kinase (PI3K) or mitogen-activated protein kinase (MAPK) pathway, such as <i>RAS</i> and <i>BRAF</i>, or by the rearrangement of growth factor receptor tyrosine kinase genes such as <i>RET/PTC</i>.
|
29163356 |
2017 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that miR-145 is a master regulator of thyroid cancer growth, mediates its effect through the PI3K/Akt pathway, is secreted by the thyroid cancer cells, and may serve as an adjunct biomarker for thyroid cancer diagnosis.
|
24781864 |
2014 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This genotype-based targeting of the PI3K/Akt pathway using Akt and mTOR inhibitors may offer an effective therapeutic strategy for thyroid cancer and warrants further studies.
|
19706758 |
2009 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These distinct genetic alterations constitutively activate the MAPK, PI3K and β-catenin signaling pathways, which have been implicated in thyroid cancer development and progression.
|
23128507 |
2013 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article, the role of PI3K pathway activation in thyroid cancer is discussed, with a focus on recent advances.
|
18502332 |
2008 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, our data showed that the c-Met/PI3K/Akt signaling pathway was responsible for the inhibitory effect of ING5 on the thyroid cancer.
|
29272787 |
2018 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Targeting mutations leading to PI3K/mTOR/Akt activation are of interest in thyroid cancer.
|
29301825 |
2018 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study demonstrates a genetic selectivity of MK2206 in inhibiting thyroid cancer cells by targeting the PI3K/Akt pathway, supporting a clinical trial in thyroid cancer.
|
21289267 |
2011 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechanically, our data demonstrated that tumor-promoting role of N-cadherin in thyroid cancer was closely related to the activities of the MAPK/Erk, the phosphatidylinositol-3-kinase (PI3K)/Akt and p16/Rb signaling pathways in addition to affecting the EMT process.
|
28042956 |
2017 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present review focuses on the most recent developments on the role of the PI3K/Akt pathway in the pathogenesis of non-medullary TC and will provide insight into how this pathway can be targeted either alone or in the context of multimodal therapeutic strategies for treatment of advanced TC.
|
26138515 |
2015 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PI3K/Akt pathway may thus be a major therapeutic target in thyroid cancers.
|
17317825 |
2007 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As in many other human cancers, overactivation of the phosphotidylinositol 3-kinase (PI3K)/Akt signaling pathway occurs frequently in thyroid cancer, but the mechanism is not completely clear.
|
15928251 |
2005 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As phosphoinositide 3-kinase/protein kinase-B (PI3K/AKT) signaling is a fundamental oncogenic driver in many thyroid cancers, we explored a potential role for miR-146b and its target genes in PI3K/AKT activation.
|
29353884 |
2018 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Long Noncoding RNA LINC003121 Inhibits Proliferation and Invasion of Thyroid Cancer Cells by Suppression of the Phosphatidylinositol-3-Kinase (PI3K)/Akt Signaling Pathway.
|
29969438 |
2018 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our aim was to determine the therapeutic efficacy of simultaneously targeting these pathways in thyroid cancer with a single agent and to evaluate biomarkers of treatment response.<b>Experimental Design:</b> CUDC-907 is a first-in-class compound, functioning as a dual inhibitor of HDACs and the PI3K/AKT pathway.
|
28600475 |
2017 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic alterations in pathways, including the mitogen‑activated protein kinase (MAPK)/extracellular signal‑regulated kinase (Erk) and phosphatidylinositol‑3‑kinase (PI3K)/protein kinase B (Akt) pathways, are the driving force behind the development of differentiated thyroid cancer cases into aggressive and undifferentiated forms of thyroid cancer.
|
30365150 |
2019 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, combined PI3K/mTOR and CDK4/6 inhibition is a highly promising novel approach for the treatment of aggressive, therapy-resistant thyroid cancer.
|
30699064 |
2019 |
|
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we identify Janus kinase/signal transducers and activators of transcription (STAT) and phosphatidyl inositol 3-kinase (PI3K)/AKT as the down-stream pathways through which these cytokines confer resistance to cell death in thyroid cancer.
|
19638576 |
2009 |